Case Report
Multimodality evaluation and ultrasound-guided aspiration of a biopsy-proven inspissated clogged milk duct: a case report
Translational Breast Cancer Research
2025;
6:
30
.
(30 July 2025)
Editorial Commentary
Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04
Translational Breast Cancer Research
2025;
6:
29
.
(30 July 2025)
Editorial Commentary
DESTINY-Breast09, new breakthroughs in first-line therapy for HER2-positive advanced breast cancer
Translational Breast Cancer Research
2025;
6:
28
.
(30 July 2025)
Editorial Commentary
Omitting sentinel lymph node biopsy in early breast cancer: too bold or the future?
Translational Breast Cancer Research
2025;
6:
27
.
(30 July 2025)
Editorial Commentary
Key breast cancer highlights from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Translational Breast Cancer Research
2025;
6:
26
.
(30 July 2025)
Mini-Review
Trastuzumab deruxtecan in patients with bone metastases from HR+/HER2-low breast cancer: efficacy enhanced by denosumab
Translational Breast Cancer Research
2025;
6:
25
.
(30 July 2025)
Review Article
Precision therapy in metastatic breast cancer: the current landscape of molecular alteration-based therapies
Translational Breast Cancer Research
2025;
6:
24
.
(30 July 2025)
Review Article
Escalation and optimisation of primary breast cancer treatment with antibody-drug conjugates
Translational Breast Cancer Research
2025;
6:
23
.
(30 July 2025)
Original Article
Real-world efficacy and safety of trastuzumab deruxtecan in heavily pre-treated HER2-low metastatic breast cancer across distinct immunohistochemistry statuses
Translational Breast Cancer Research
2025;
6:
22
.
(30 July 2025)
Expert Consensus
Chinese expert consensus on clinical diagnosis and treatment of breast cancer targeting HER2
Translational Breast Cancer Research
2025;
6:
21
.
(30 July 2025)
